Biotech China 2014

View Profile


Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2010 Contributions of Change in Clinical Status Parameters to Patient Global Impression of Change (PGIC) Scores Among Persons with Fibromyalgia Treated With Milnacipran or Placebo Pain 2010; 149:373-8
2. 2010 A first step to assess harm and benefit in clinical trials in one scale J Clin Epi 2010; 63:627-32
3. 2010 Elevated liver enzyme tests among rheumatoid arthritis and psoriatic arthritis patients treated with methotrexate and/or leflunomide Ann Rheum Dis 2010; 69:43-7.
4. 2010 Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension. Results of a systematic literature analysis by the EPOSS group J Rheumatol 2010; 37:105-15.
5. 2010 Flare” and Disease Worsening in Rheumatoid Arthritis: Time for a Definition Int J Rheum 2009; in press
6. 2010 Risk of Elevated Liver Enzymes Associated with TNF Inhibitor Utilization in Patients with Rheumatoid Arthritis Ann Rheum Ds 2010; 69:1612-17
7. 2010 Newer Biologic Agents Improve Health Related Quality of Life and Productivity in Rheumatoid Arthritis Drugs 2010; 70:121-145
8. 2010 Systemic Lupus Erythematosus-Related Interstitial Lung Disease Current Rheumatology Reviews 2010; 6:99-107.
9. 2010 Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol Rheumatology 2010; 10.1093/rheumatology/keq109
10. 2010 Interstitial Lung Disease with Connective Tissue Diseases Current Rheumatology Reviews 2010; 6:88-90
11. 2010 Flare Consensus Initiative: International Consensus to Define Disease Flare in Lupus Lupus 2010; in press
12. 2010 OMERACT How to get into the “Act”. The Rheumatologist 2010; 4:1, 24-5
13. 2009 Variation in Outcome Measures in Hip and Knee Arthroplasty Clinical Trials: A Proposed Approach to Achieving Consensus J Rheumatol 2009; 36:2050-6
14. 2009 International Consensus Conference on outcome measures in rheumatology clinical trials J Rheumatol 2009; 36:1765-8.
15. 2009 Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy:  the FAST4WARD study Ann Rheum Dis 2009; 68:805-11
16. 2009 Efficacy and Safety of Certolizumab Pegol Plus Methotrexate in Active Rheumatoid Arthritis: The RAPID 2 Study. A randomized controlled trial Ann Rheum Dis 2009; 68:797-804
17. 2009 Evaluation of Composite Measures of Treatment Response Without Acute Phase Reactants in Patients with Rheumatoid Arthritis Rheumatology 2009: 48:686-90
18. 2009 Measuring worker productivity: frameworks & measures J Rheumatol 2009: 36:2100–9
19. 2009 Novel Evidence-Based Systemic Lupus Erythematosus Responder Index Arth Rheum 2009; 61:1143-51
20. 2009 Health-related quality-of-life measures and analyses in rheumatic diseases Contemp Topics Rheum Arthritis.2009; 3:5-10.
21. 2009 Rheumatoid Arthritis: Next-Generation Biologic Therapies [Medscape]. http://cme.medscape.com/viewarticle/704075.   
22. 2009 Spondyloarthritis is associated with poor function and physical health related quality of life J Rheumatol 2009; 36:1012-1020
23. 2009 Randomized Controlled Trial Design in Rheumatoid Arthritis – The Past Decade Arth Research Therapy 2009; 11: 205-15.
24. 2009 Health care utilization in patients with spondyloarthropathies Rheumatology 2009; 48:272-6
25. 2009 The Impact of Rheumatoid Arthritis and Treatment on Patients’ Lives Clin Exp Rheum 2009; in press.
26. 2009 Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: a randomized controlled trial Arth Res Ther 2009; 11:R170.
27. 2009 Viewpoint: Use of “Spydergrams” to present and interpret Health related quality of life data across rheumatic diseases Ann Rheum Ds 2009; 68:1800-04
28. 2009 Effect of certolizumab pegol with methotrexate on home and workplace productivity and social activities in patients with active rheumatoid arthritis Arth Rheum 2009; 61:1592-600
29. 2009 Fibromyalgia Syndrome Module at OMERACT 9 J Rheumatol 2009; 36:2318-29
30. 2009 Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome J Rheumatol 2009; 36:2330-4
31. 2009 Measures of Response in Clinical Trials of Systemic Sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in PAH Related to Systemic Sclerosis (EPOSS). J Rheumatol 2009; 36:2356-61
32. 2009 The OMERACT-ICF Reference Group: Integrating the ICF into the OMERACT process: Opportunities and challenges J Rheumatol 2009; 36:2057-60
33. 2009 Developing a Standardized Definition of Disease “Flare” in Rheumatoid Arthritis (OMERACT 9 Special Interest Group J Rheumatol 2009; 36:2335-41
34. 2009 How to Ascertain Drug Safety in the Context of Benefit. Controversies and Concerns J Rheumatol 2009; 36:2114-21
35. 2009 Observations of the OMERACT Drug Safety Summit, May 2008 J Rheumatol 2009; 36:2110-13
36. 2008 Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations Ann Rheum Dis 2008; 67:1360-4
37. 2008 Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations Arth Rheum 2008; 59:1371-7
38. 2008 Certolizumab Pegol Plus Methotrexate Is Significantly More Effective Than Placebo Plus Methotrexate in Active Rheumatoid Arthritis: The RAPID 1 Study Arth Rheum 2008; 58:3319-29
39. 2008 An Update to ‘Take Two and Call Me in the Morning.’ The Rheumatology Report; Summer 2008: 9-10
40. 2008 Effects of Prasterone on Bone Mineral Density in Women with Active Systemic Lupus Erythematosus Receiving Chronic Glucocorticoid Therapy J Rheumatol 2008; 35:1567-75
41. 2008 Gout is associated with more comorbidities, poorer Health Related Quality of Life and higher health care utilization in US Veterans Ann Rheum Dis 2008; 67:1310-6
42. 2008 TNF Antagonist Responsiveness in a United States Rheumatoid Arthritis Cohort Am J Med 2008; 121:532-8
43. 2008 A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic Gout Ann Rheum Dis 2008; 67: 888-91.
44. 2008 Treatment-Related Improvement in Physical Function Varies with Duration of Rheumatoid Arthritis; A Pooled Analysis of Clinical Trial Results Ann Rheum Dis 2008; 67:238-243
45. 2008 Improved Health-Related Quality of Life with Effective Disease-Modifying Antirheumatic Drugs: Evidence from Randomized Controlled Trials Am J Managed Care 2008; 14:234-54
46. 2007 Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of quantitative hierarchical levels of evidence schema J Rheumatol 2007; 34:607-615
47. 2007 Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema J Rheumatol 2007; 34:607-15
48. 2007 Clinical Evidence for Utilization of the A3 Adenosine Receptor as a Target to Treat Rheumatoid Arthritis: Data from a Phase II Clinical Trial J Rheumatol 2007; 34: 41-8
49. 2007 Editorial: Long Term Treatment Benefits are Best Reflected in Patient Reported Outcomes J Rheumatol 2007; 34: 2317-9
50. 2007 A novel means to demonstrate early efficacy of a product in Systemic Lupus Erythematosus Current Rheum Reports 2007; 9: 27-30.
51. 2007 In Patients with Cardiovascular Risk Receiving Low Dose Aspirin, is a COX-2 Selective Agent Preferable to nsNSAIDs for Antiinflammatory Therapy? Lancet 2007; 370: 2138-57
52. 2007 Outcome measures in rheumatoid arthritis: the OMERACT process Expert Reviews Clin Immun 2007; 3:271-5.
53. 2007 Interleukin-6 Inhibition: Tolerability profile and clinical implications. Bulletin of NYU Hospital for Joint Diseases 2007; 65:S21-4
54. 2007 Rheumatoid Arthritis Consult Collection. Selective T-cell costimulation modulation: A new approach to treating rheumatoid arthritis Am J Orthop 2007; 8: 8-14
55. 2007 OMERACT: An international initiative to improve outcome measurement in rheumatology Trials 2007: 8:38 
56. 2007 Worker Productivity Outcome Measures in Arthritis J Rheumatol 2007; 34:1372-80
57. 2007 Systemic Sclerosis – Continuing progress in developing clinical measures of response J Rheumatol 2007; 34:1194-1200
58. 2007 Consensus on a core set domains for psoriatic arthritis J Rheumatol 2007; 34:1167-70
59. 2007 Outcome measures in psoriatic arthritis J Rheumatol 2007; 34:1159-1166.
60. 2007 Computer based methods for measurement of joint space width: update of an ongoing OMERACT project. J Rheumatol 2007; 34:874-883
61. 2007 Health-related quality of life in patients with systemic lupus erythematosus: an update Ann Acad Med Singapore 2007; 36:115-122
62. 2007 OMERACT 8 – 8th international consensus conference on outcome measures in rheumatology clinical trials J Rheumatol 2007; 34:599
63. 2007 Lessons learned from clinical trials in SLE Autoimmunity Reviews 2007; 6:209-214
64. 2007 Biologic therapies in rheumatology: lessons learned, future directions Nature Reviews Drug Discovery 2007; 6:75-92.
65. 2006 Leflunomide in juvenile idiopathic arthritis Future Rheumatol 2006; 1:673-682.
66. 2006 Risedronate Decreases Biochemical Markers of Cartilage Degradation but Does Not Decrease Symptoms or Slow X-Ray Progression in Patients with Medical Compartment Osteoarthritis of the Knee: Result of the Two-Year Multinational Knee OA Structural Arthritis (KOSTAR) Study Arth Rheum 2006; 54:3494-3507
67. 2006 Sustained benefit in Rheumatoid Arthritis following one course of rituximab: improvements in physical function over 2 years Rheumatology 2006; 45:1505-1513.
68. 2006 Monitoring disease activity of rheumatoid arthritis in clinical practice: contributions from clinical trials Nature Clin Prac Rheum 2006; 2:611-18
69. 2006 Cardiovascular Effect of Selective COX-2 Inhibition: Is There a Class Effect? The International COX-2 Study Group J Rheumatol 2006; 33:1403-8.
70. 2006 An integrated analysis of 5 double blind randomized controlled trials of the safety and efficacy of a hyaluronan product for intra-articular injection in osteoarthritis of the knee. Osteoarthritis Cart 2006; 14:859-66
71. 2006 Are American College of Rheumatology 50% Response Criteria (ACR 50) Superior to 20% Criteria (ACR20) to Distinguish Active from Comparator Treatment in Rheumatoid Arthritis Clinical Trials Reported Since 1997? A Metaanalysis of Discriminant Capacities Ann Rheum Ds 2006; 65:1602–7
72. 2006 Expectations from patients with rheumatoid arthritis regarding COX-2s – cutting to the heart of the matter J Cardiovasc Pharm 2006; 47: S55-9
73. 2006 Measuring quality in arthritis care; the Arthritis Foundation’s Quality Indicator Set for rheumatoid arthritis Semin Arth Rheum 2006; 35:205-7
74. 2006 Patient reported pain is central to OMERACT rheumatology core measurement sets. DIA Journal 2006; 40:111-116
75. 2005 Expert Panel report use of combination of leflunomide with biological agents in treatment of RA. J Rheumatol 2005; 32:1620-31
76. 2005 Fibromyalgia Syndrome J Rheumatol. 2005; 32:2270-7
77. 2005 Outcome Measures in Psoriatic Arthritis J Rheumatol. 2005; 32: 2262-9.
78. 2005 Measurement of joint space width and erosion size J Rheumatol. 2005; 32: 2456-61
79. 2005 Minimal disease activity for rheumatoid arthritis: a preliminary definition J Rheumatol 2005; 32:2016-24.
80. 2005 Omeract 7 – 7th International Consensus Conference on Outcome Measures in Rheumatology Clinical Trials J Rheumatol 2005; 32: 2014-5.
81. 2005 Improvement in Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus following Sustained Reductions in Anti-dsDNA Antibodies Expert Review Pharmacoeconomics & Outcomes Research 2005: 5:317-26
82. 2005 Relationship between anti dsDNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arth Rheum 2005; 52: 1129-37
83. 2005 Physical Function and Health-Related Quality of Life: Analysis of 2-Year Data from Randomized, Controlled Studies of Leflunomide, Sulfasalazine, or Methotrexate in Patients with Active Rheumatoid Arthritis J Rheumatol 2005; 32: 590-601.
84. 2005 Expanding the Definition of Clinical Differences: From Minimally Clinically Important Differences (MCID) to Really Important Differences (RID). Analyses in 8,931 Patients with Rheumatoid Arthritis J Rheumatol 2005; 32: 583-9.
85. 2005 Leflunomide or Methotrexate for the Treatment of Juvenile Rheumatoid Arthritis NEJM 2005: 352:1655-66
86. 2005 Long-term Open-label Study of Preliminary Safety and Efficacy of Leflunomide in Polyarticular Course Juvenile Rheumatoid Arthritis (JRA) Arth Rheum 2005: 52: 554-562
87. 2005 Pharmacovigilance in the Treatment of Rheumatoid Arthritis J Rheumatol 2005; 32: in press
88. 2005 Leflunomide improves physical function and health-related quality of life when added to methotrexate in patients with active rheumatoid arthritis J Clin Rheum 2005; 32:590-601
89. 2004 Efficacy and Safety of Leflunomide 10 mg vs 20 mg once daily in patients with active RA: A multinational double blind randomized trial Rheumatology 2004: 43:744-9
90. 2004 A world without Vioxx: To COX-2 or not to COX-2. Cleveland Clinic J Med 2004: 71:849-55
91. 2004 Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus Arth Rheum 2004; 50:2858-68
92. 2004 Combination leflunomide and methotrexate therapy for patients with active rheumatoid arthritis failing methotrexate monotherapy: an open-label extension of a randomized, double-blind, placebo-controlled trial J Rheumatol 2004; 31: 1521-1531.
93. 2004 Longer Term Benefits of Treating Rheumatoid Arthritis: Assessment of Radiographic Damage and Physical Function over 2 years in Clinical Trials Clin Exp Rheum. 2004: 22: S57-64
94. 2004 Benefits vs Risks of TNF inhibitors New Developments in Rheumatic Diseases 2004; 2: 1-8
95. 2004 Effects of the cyclooxygenase 2 specific inhibitor valdecoxib versus NSAIDs and placebo on cardiovascular thrombotic events in patients with arthritis Am J Therapeutics 2004; 11:244-250
96. 2004 Leflunomide in combination therapy J Rheumatol 2004; 31:S24-30
97. 2004 Leflunomide: A manageable safety profile J Rheumatol 2004: 31:S21-24.
98. 2004 The efficacy of leflunomomide monotherapy in rheumatoid arthritis: towards the goal of disease modifying antirheumatic drug therapy J Rheumatol 2004; 31: S13-20
99. 2004 The role of Interleukin-1 in bone resorption in rheumatoid arthritis Rheumatology 2004; 43: i10-16
100. 2004 Lessons Learned and Future Directions Lupus 2004; 13:406-411
101. 2004 Patient versus Physician-Reported Outcomes in Rheumatoid Arthritis Patients Treated with Recombinant Interleukin-1 Receptor Antagonist (Anakinra) Therapy Rheumatology 2004: 43: 648-95
102. 2004 Patient reported outcomes better discriminate active treatment from placebo in RA clinical trials. Rheumatology 2004: 43:640-7
103. 2004 Variability of precision in scoring radiographic abnormalities in RA J Rheumatol 2004: 31:1062-72
104. 2004 Long-term evaluation of radiographic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years: concise report Ann Rheum Ds 2004: 63:737-9
105. 2004 Concise Communication: Counterpoint: From the Trenches; A Commentary on “Add-on or step-up trials for new drug development in rheumatoid arthritis: a new standard? Arth Rheum 2004: 50:1344-8. 648-56.
106. 2004 Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage. 2004; 12:389-99
107. 2004 Outcome Measures in Randomized Controlled Trials in Osteoarthritis Curr Rheumatol Reports 2004; 6:20-30
108. 2003 Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria J Rheumatol. 2003; 30:1648-54.
109. 2003 MCID/Low disease activity state workshop: summary, recommendations, and research agenda J Rheumatol 2003; 30: 1115-8
110. 2003 MCID/Low disease activity state workshop: low disease activity state in rheumatoid arthritis J Rheumatol 2003; 30: 1110-11
111. 2003 The use of low dose glucocorticoid therapy in early rheumatoid arthritis Clin Exp Rheum 2003; 21: S186-190
112. 2003 Adalimumab, a Fully Human Anti–TNF-a Monoclonal Antibody, and Concomitant Standard Antirheumatic Therapy for the Treatment of Rheumatoid Arthritis: Results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) J Rheumatol 2003: 30: 2563-71
113. 2003 . Repair of erosions in rheumatoid arthritis does occur. Results from 2 studies by the OMERACT Subcommittee on Healing of Erosions J Rheumatol. 2003; 30: 1102-7
114. 2003 An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the ACR 20% response criteria (ACR20) or the disease activity score (DAS) in a RA clinical Trial Arth Rheum 2003; 48: 625-30
115. 2003 Investigator Consortium and Crawford B: Improvement in health-related quality of life in SLE Patients Enrolled in a Randomized Clinical Trial Comparing LJP 394 Treatment with Placebo Lupus 2003; 12:677-86
116. 2003 LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double blind, placebo controlled study Arth Rheum 2003; 48: 442-54
117. 2003 Radiographic Data from recent randomized controlled trials in rheumatoid arthritis: what have we learned? Arth Rheum 2003: 48:21-34.
118. 2002 Concomitant Leflunomide Therapy in Patients with Active Rheumatoid Arthritis despite Stable doses of Methotrexate Annals Int Med 2002; 137:726-33
119. 2002 Predictors and outcomes of scleroderma renal crisis: data from the high dose vs low dose D-penicillamine in early diffuse systemic sclerosis trial Arth Rheum 2002; 46:2836-7.
120. 2002 Using estimated yearly progression rates to compare radiographic data across recent randomized controlled trials in rheumatoid arthritis Ann Rheum Ds 2002; 61: ii64-ii66
121. 2002 Corticosteroid Sparing Efficacy of DHEA for female patients with mild to moderate systemic lupus erythematosus. Arth Rheum 2002; 46:1820-9
122. 2002 The effects of disease modifying anti-rheumatic drugs on the HAQ score. Lessons from the leflunomide clinical trials database. Rheumatology 2002; 41: 899-909
123. 2002 The Risk of Cardiovascular Thrombotic events with selective Cyclooxygenase-2 Inhibitors Arth Rheum 2002; 47:349-55.
124. 2002 How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion Arth Rheum 2002; 47: 215-8
125. 2002 Economic comparison of leflunomide and methotrexate in patients with active rheumatoid arthritis Pharmacoeconomics 2002; 20:61-70.
126. 2001 Review: Monoclonal antibodies and other biologic therapies Lupus 2001; 10: 216-21
127. 2001 Leflunomide for rheumatoid arthritis: Defining its role J Musculoskeletal Med 2001; 18:277-84
128. 2001 Assessing efficacy measures for severe rheumatoid arthritis Pharm Therapeutics Supp; Mar 2001:3-7
129. 2001 Patient based method of assessing adverse events in clinical trials in rheumatology: the revised Stanford Toxicity Index. J Rheum 2001; 28:1188-91
130. 2001 A proposal for developing a large patient population cohort for longterm safety monitoring in rheumatoid arthritis J Rheum 2001; 28:1170-3.
131. 2001 Towards a Common Understanding of Comparative Toxicity/Safety Profiles for Antirheumatic Therapies J Rheum 2001; 28:1163-69.
132. 2001 New therapies in development for autoimmune diseases: their rationale for combination treatment Sem Immunopathology 2001; 23:4-61
133. 2001 Two year treatment of active rheumatoid arthritis with leflunomide compared with methotrexate Arth Rheum 2001; 40:1984-92
134. 2001 Radiography of rheumatoid arthritis in the time of increasing drug effectiveness Curr Rheum Reports 2001; 3:46-52
135. 2001 Minimum clinically important differences in plain films in RA J Rheum 2001; 28:914-7
136. 2001 Recent Rheumatoid Arthritis Clinical Trials Using Radiographic Endpoints – Updated research agenda J Rheum 2001; 28:887-9
137. 2000 Biologic Agents in the treatment of rheumatoid arthritis Current Pharmaceutical Biotechnology 2000; 1:217-33
138. 2000 Recent developments for optimal end-points in rheumatoid arthritis clinical studies Ds Manage Health Outcomes 2000; 8:87-97
139. 2000 A proposal for developing a large patient population cohort for long-term safety monitoring in rheumatoid arthritis J Rheum 2000; 27:827-30
140. 2000 A meta-analysis of treatment termination rates in rheumatoid arthritis patients receiving disease modifying anti-rheumatic drugs Rheumatology 2000; 39: 975-81
141. 2000 Efficacy and safety in clinical trials for the treatment of rheumatoid arthritis. Drugs Today 2000; 36:383-94
142. 2000 Issues Involved in a Metaanalysis of RA Radiographic Progression J Rheum 2000; 27: 544-8
143. 2000 Endpoints: Consensus Recommendations from OMERACT IV Lupus 2000; 9:322-7
144. 2000 Treatment with Leflunomide Slows Radiographic Progression of RA – Results from 3 Randomized Controlled Trials of Leflunomide in Patients with Active Rheumatoid Arthritis Arth Rheum 2000; 43:495-505
145. 2000 Clinical Improvement as Reflected in Measures of Function and Health Related Quality of Life: Sensitivity and Relative Efficiency to Detect a Treatment Effect in a 12 month Placebo Controlled Trial Comparing Leflunomide with Methotrexate Arth Rheum 2000; 43:506-14
146. 2000 Leflunomide, an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune disease Immunopharmacology 2000; 47:273-89
147. 1999 Imaging in Rheumatoid Arthritis: Results of Group Discussions J Rheum 1999; 26:749-51
148. 1999 Leflunomide for the treatment of rheumatoid arthritis Bull Rheum Ds 1999; 48:8
149. 1999 Steroid withdrawal favours joint erosion in rheumatoid arthritis Clin Exper Rheum 1999; 17:519-20
150. 1999 Combination biologic therapy Clinical Exper Rheum 1999; 17:S21-4
151. 1999 Mechanism of Action for Leflunomide in Rheumatoid Arthritis. Clinical Immunology 1999; 93:198-208
152. 1999 Advances in the Treatment of Rheumatoid Arthritis Clinical Cornerstone 1999; 2:38-47
153. 1999 Biologic Agents and Innovative Interventional Approaches in the Management of SLE Curr Opin Rheum 1999; 11:330-40
154. 1999 Function and health related quality of life—results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis Arth Rheum 1999; 42:1870-8
155. 1999 Treatment of Active Rheumatoid Arthritis with Leflunomide Compared to Placebo and Methotrexate. Archives Int Med 1999; 159:2542-50
156. 1999 Efficacy, Safety and Pharmacokinetics of the combination of methotrexate and leflunomide in patients with active rheumatoid arthritis Arth Rheum 1999; 42:1322-8
157. 1999 Randomized Clinical Trials and Longitudinal Observational Studies in SLE: Consensus on a Preliminary Core Set of Outcome Domains J Rheum 1999; 26: 504-7
158. 1999 Outcome Measures in Clinical Trials in Systemic Lupus Erythematosus J Rheum 1999; 26: 490-7
159. 1998 The OMERACT Filter for Outcome Measures in Rheumatology Editorial. J Rheum 1998; 25:198-9
160. 1998 T cell receptor peptide vaccination in rheumatoid arthritis: a placebo controlled trial using a combination of Vβ3, 14 and 17 peptides Arth Rheum 1998; 41:1919-29.
161. 1998 A Survey of US and Canadian rheumatologists’ therapeutic choices in moderate and aggressive rheumatoid arthritis J Rheum 1998; 25:2331-8.
162. 1998 Use of the Interleukin-2 (IL-2) Fusion Protein DAB389 IL-2 for the Treatment of Psoriasis Dermatologic Therapy 1998; 5:48-63
163. 1997 Future use of biologic agents alone and in combination for the treatment of rheumatoid arthritis J Rheum 1997; 57:17-49
164. 1997 Clinical response to nonsteroidal antiinflammatory drugs Editorial. Arth Rheum 1997; 40: 1940-43
165. 1997 Biologic Agents and Innovative Interventional Approaches in the Management of SLE Curr Opin Rheum 1997; 9:410-20
166. 1997 Workshop Report: WHO/ILAR Taskforce on Quality of Life J Rheum 1997; 24: 1630-3.
167. 1997 Meeting Report: Innovative Therapies in Autoimmune Diseases ID Research Alert, Weekly Highlights June 11, 1997:20-25.
168. 1997 Recommendations for a Core Set of Outcome Measures for Future Phase III Trials in Knee, Hip and Hand Osteoarthritis J Rheum 1997; 24:799-802
169. 1996 Proceedings: Biologic Agents in Autoimmune Disease IV Conference Summary and Final Comments pp. 233-236
170. 1996 The Future Use of Biologic Agents in Combination for Treatment of Rheumatoid Arthritis J Rheum 1996; 23:91-6
171. 1996 A Double Blind, Placebo Controlled Study of Anti-CD 5 Immunoconjugate in Patients with Rheumatoid Arthritis. Arth Rheum 1996; 39:1002-8
172. 1995 Safety and Effectiveness of Leflunomide in the Treatment of Patients with Active Rheumatoid Arthritis - Results of a Randomized Double Blind Placebo Controlled Phase II Trial Arth Rheum 1995; 38:1595-1603
173. 1995 OMERACT II: The biologics perspective J Rheum 1995; 22:1415-7.
174. 1995 American College of Rheumatology Preliminary Definition of Improvement in Rheumatoid Arthritis Arth Rheum 1995; 38:727-35.
175. 1995 Immunologic Assessment during Treatment of Rheumatoid Arthritis with Anti-CD5 Immunoconjugate J Rheum 1995; 22:207-13
176. 1994 Biologic Interventions in Rheumatoid Arthritis J Biotechnology in Health Care 1994-5; 1: 283-302 and 1: 377-95
177. 1994 Administration of an anti-CD5 immunoconjugate to patients with rheumatoid arthritis. Selective decrease in synovial collagenase gene expression Arth Rheum 1994; 37:193-200
178. 1994 Evaluating Biologic Agents in Rheumatoid Arthritis: A Framework for Clinical Trials. Editorial. J Rheum 1994; 21:1390-2.
179. 1994 Are There Special Considerations Relevant to Trials of Biologic Agents? J Rheum 1994; 21: 41-5
180. 1994 A pilot study of anti CD5 Ricin A chain immunconjugate in Systemic Lupus Erythematosus. J Rheum 1994; 21:2068-70
181. 1994 Treatment with an Anti-CD5 Immunoconjugate: Effect on Peripheral T cells and in vitro Assays of Immune Function in Patients with Rheumatoid Arthritis J Rheum 1994; 21:596-604
182. 1993 OMERACT and the Clinical Evaluation of New Therapeutic Agents: A Bird's Eye View J Rheum 1993; 20:588-9
183. 1993 Differential Patterns of Response to Treatment with an Anti-CD5 Immunoconjugate in Patients with Rheumatoid Arthritis Clin Exper Rheum 1993; 11:161-3.
184. 1993 Effects of Administration of an Anti-CD5 Immunoconjugate in Rheumatoid Arthritis: Results of Two Phase II Studies Effects of Administration of an Anti-CD5 Immunoconjugate in Rheumatoid Arthritis: Results of Two Phase II Studies
185. 1993 In Vivo T Cell Depletion in Rheumatoid Arthritis is Associated with Increased In Vitro IgM Rheumatoid Factor Synthesis Clin Immunol Immunopath 1993; 67:124-9.
186. 1992 The Emerging Role of Biologics in Rheumatic Diseases Perspectives in Pediatric Rheumatology". J Rheum 1992; 19: 40-5
187. 1991 Use of an Anti-CD5 Immunoconjugate in Rheumatoid Arthritis Proceedings: Early Decisions in DMARD Development II: Biologic Agents in Autoimmune Disease, Strand, V. Ed. Amento E, Scribner C. Assoc Eds. Arthritis Foundation
188. 1991 Trial Design and Concepts Specific to Biologic Agents Proceedings: Early Decisions in DMARD Development II: Biologic Agents in Autoimmune Disease, Strand V. Ed. Amento E, Scribner C. Assoc Eds. Arthritis Foundation
189. 1988 Ganciclovir Treatment of Life-or-Sight-Threatening Cytomegalovirus Infection: Experience in 314 Immuno-Compromised Patients Rev Infect Dis 1988; 10:S490-94
190. 1984 Non-Steroidal Anti-Inflammatory Drugs . Luke's Hospital Drug and Therapeutics Bulletin, Feb. 1984
191. 1983 Adult Arthritis: Drugs and Remedies American Journal of Nursing 1983; 83:266-270
192. 1983 Natural Killing Activity in Sjogren's Syndrome Arth Rheum 1983; 26:954-60
193. 1983 Lymphocyte Subsets in Sjogren's Syndrome: A Quantitative Analysis Using Monoclonal Antibodies and the Fluorescence-Activated Cell Sorter J Clin Lab Immunol 1983; 10:63-9
194. 1982 Antibody to Cytomegalovirus in Patients with Sjogren's Syndrome. Arth Rheum 1982; 25:260-5
195. 1981 Concomitant Renal and Hepatic Failure Treated by Polyacrylonitrile Membrane Hemodialysis. Inter J Artif Organs 1981; 3:136-9
196. 1980 Advances in the Diagnosis and Concept of Sjogren's Syndrome Bull Rheum Ds 1980; 30:1046-52
197. 1978 Essential Hypernatremia Am.J.Med.Sci 1978; 8:353-8
198. 1974 Plasminogen Activator and Alkaline Phosphatase in Guinea Pig Vessels Arch Path Lab Med 1974.
199. 1972 Fibrinolytic Activity in the Closed Ductus Arteriosus Experientia 1972; 28:448-9


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.